GY48LS6

Кеймбридж
[ ]
Вакцина ChAdOx1
Международное непатентованное наименование Вакцина ChAdOx1
Торговое наименование -
Производитель, страна University of Oxford, United Kingdom
Опыт использования

Non-replicating chimpanzee adenovirus vector. Phase 1/2 trial with 510 subjects aged 18-55 at four centers in the United Kingdom. The trial will test safety and immunogenicity of one or two doses of the vaccine, and is expected to be completed in May 2021.

Публикации COVID-19

Neeltje van DoremalenTeresa LambeAlexandra Spencer, et al. ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques. May 13, 2020. DOI: 10.1101/2020.05.13.093195

 

Morven WilkieIman Satti, et al. A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime – MVA85A boost in healthy UK adults. Vaccine. Volume 38, Issue 4, 22 January 2020, Pages 779-789. DOI: 10.1016/j.vaccine.2019.10.102.

 

Morven WilkieIman Satti, et al. A Phase I Trial Evaluating the Safety and Immunogenicity of a Candidate Tuberculosis Vaccination Regimen, ChAdOx1 85A Prime - MVA85A Boost in Healthy UK Adults. Vaccine. 2020 Jan 22;38(4):779-789. DOI: 10.1016/j.vaccine.2019.10.102.

Клинические исследования
1.
Название протокола A Phase I/II Study to Determine Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 in UK Healthy Adult Volunteers
Дата начала и окончания КИ April 2020 - May 2021
Название организации, проводящей КИ University of Oxford
Страны United Kingdom
Фаза I-II
Кол-во пациентов 510
2.
Название протокола A Phase Ib Study to Determine the Safety and Immunogenicity of the Candidate Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Vaccine ChAdOx1 MERS in Healthy Adult Middle Eastern Volunteers
Дата начала и окончания КИ December 17, 2019 - January 1, 2021
Название организации, проводящей КИ King Abdullah International Medical Research Center
Страны Saudi Arabia
Фаза Ib
Кол-во пациентов 24